	US 7,531,175 B2
	Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules
Man Sung Co, Cupertino, Calif. (US); Maximiliano Vasquez, Palo Alto, Calif. (US); Beatriz Carreno, Acton, Mass. (US); Abbie Cheryl Celniker, Newton, Mass. (US); Mary Collins, Natick, Mass. (US); Samuel Goldman, Acton, Mass. (US); Gary S. Gray, Brookline, Mass. (US); Andrea Knight, Hampton, N.H. (US); Denise O'Hara, Reading, Mass. (US); Bonita Rup, Reading, Mass. (US); and Geertruida M. Veldman, Sudbury, Mass. (US)
Assigned to Genetics Institute LLC, Madison, N.J. (US)
Filed on Nov. 12, 2004, as Appl. No. 10/986,089.
Application 10/986089 is a division of application No. 09/339596, filed on Jun. 24, 1999, granted, now 6,913,747.
Application 09/339596 is a continuation in part of application No. 09/249011, filed on Feb. 12, 1999, granted, now 6,972,125.
Prior Publication US 2005/0208042 A1, Sep. 22, 2005
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/395 (2006.01); C07K 16/28 (2006.01)

U.S. Cl. 424—153.1 [424/130.1; 424/133.1; 424/140.1; 424/141.1; 424/143.1; 424/173.1; 530/387.1; 530/387.3; 530/388.1; 530/388.2; 530/388.22; 530/388.7; 530/388.73]

61 Claims

1. A method of inhibiting the interaction of a first cell bearing CD28 and/or CTLA4 with a second cell bearing B7-1, comprising contacting said second cell with an effective amount of a humanized immunoglobulin molecule having binding specificity for B7-1, said immunoglobulin comprising a constant region of human origin and a variable region, wherein said variable region comprises:

a) one or more complementarity determining regions derived from the 1F1 mouse monoclonal antibody (ATCC Accession No. PTA 263) and

b) one or more framework regions of human origin.